2015
DOI: 10.1186/s12876-015-0390-3
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: BackgroundGranulocyte and monocyte adsorptive apheresis (GMA) has shown efficacy in patients with active Crohn’s disease (CD). However, with routine weekly therapy, it may take several weeks to achieve remission. This study was performed to assess clinical efficacy and safety of intensive GMA in patients with active CD.MethodsIn an open-label, prospective, randomized multicentre setting, 104 patients with CD activity index (CDAI) of 200 to 450 received intensive GMA, at two sessions per week (n = 55) or one se… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
19
0

Year Published

2018
2018
2020
2020

Publication Types

Select...
2

Relationship

2
0

Authors

Journals

citations
Cited by 18 publications
(34 citation statements)
references
References 42 publications
(34 reference statements)
0
19
0
Order By: Relevance
“…Granulocyte and monocyte absorptive apheresis is available in Europe and Japan for the treatment of patients with active CD that may or may not be refractory to standard pharmacotherapy, including TNF‐α antagonists . GMA depletes activated leukocytes, particularly granulocytes and macrophages, thereby downregulating proinflammatory cytokine (IL‐1β and TNF‐α)‐induced inflammatory responses in peripheral blood mononuclear cells, resulting in amelioration of gut inflammation .…”
Section: Discussionmentioning
confidence: 99%
“…GMA depletes activated leukocytes, particularly granulocytes and macrophages, thereby downregulating proinflammatory cytokine (IL‐1β and TNF‐α)‐induced inflammatory responses in peripheral blood mononuclear cells, resulting in amelioration of gut inflammation . An open‐label prospective randomized study comparing the efficacy of intensive GMA with that of weekly GMA showed that no significant differences in remission rates between patients with intensive GMA (35.2%) and those with weekly GMA (35.6%), but time to remission was significantly shorter in the intensive GMA group (21.7 days) than in the weekly GMA group (35.4 days) without increasing the incidence of side‐effects . This suggests that GMA, which normalizes imbalances in immune profile in patients with CD, has strong and favorable impacts on the efficacy of UST.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…2) Crohn's disease Several reports have shown the efficacy of GMAA in patients with active CD. Based on data demonstrated that intensive GMAA is superior to weekly apheresis in the induction of remission for active UC, Yoshimura et al 38 performed an openlabel, prospective, randomized study to evaluate the clinical efficacy and safety of intensive GMAA in patients with active CD. The results of the study demonstrated that the time to remission was significantly shorter in CD patients treated with intensive GMAA than in those treated with weekly GMAA, despite the absence of a significant difference in remission rates between CD patients treated with intensive GMAA and those treated with weekly GMAA.…”
Section: ) Ulcerative Colitismentioning
confidence: 99%